Search results for " prognostic"

showing 10 items of 139 documents

Transfusion Need at Diagnosis or Its Development During the First Year of Diagnosis in Primary Myelofibrosis: Effect On Survival and Correlation with…

2009

Abstract Abstract 1909 Poster Board I-932 Background: The International Prognostic Scoring System (IPSS) for primary myelofibrosis (PMF) utilizes five independent predictors of inferior survival; of these, a hemoglobin level <10 g/dL has the highest impact on survival (Cervantes et al. Blood 2009;113:2895). In the current study, we examined the additional prognostic impact of transfusion need at diagnosis or becoming transfusion-dependent in the first year of diagnosis. These events were also correlated with JAK2 or TET2 mutational status. Methods: Patients were selected from the Mayo Clinic PMF database based on availability of bone marrow histology and IPSS-relevant information at diag…

medicine.medical_specialtyBlood transfusionbusiness.industryProportional hazards modelmedicine.medical_treatmentImmunologymyelofibrosisTransfusion HistoryCell BiologyHematologyBiochemistrySettore MED/15 - Malattie Del SangueSurgeryTransplantationLog-rank testInternational Prognostic Scoring SystemInternal medicineCohortmedicinebusinessSurvival analysisBlood
researchProduct

Prospective external validation of a predictive score for postoperative pulmonary complications.

2015

Abstract Background: No externally validated risk score for postoperative pulmonary complications (PPCs) is currently available. The authors tested the generalizability of the Assess Respiratory Risk in Surgical Patients in Catalonia risk score for PPCs in a large European cohort (Prospective Evaluation of a RIsk Score for postoperative pulmonary COmPlications in Europe). Methods: Sixty-three centers recruited 5,859 surgical patients receiving general, neuraxial, or plexus block anesthesia. The Assess Respiratory Risk in Surgical Patients in Catalonia factors (age, preoperative arterial oxygen saturation in air, acute respiratory infection during the previous month, preoperative anemia, upp…

medicine.medical_specialtyIMPACTRESPIRATORY-FAILUREAtelectasisMULTIFACTORIAL RISK INDEXMedicineNONTHORACIC SURGERYProspective cohort studyPOPULATIONFramingham Risk Scorebusiness.industryExternal validationRespiratory infectionmedicine.diseaseSurgeryPROGNOSTIC MODELAnesthesiology and Pain MedicinePneumothoraxINTUBATIONPredictive value of testsLOGISTIC-REGRESSION MODELSMAJOR NONCARDIAC SURGERYRisk assessmentbusinessLOGISTIC-REGRESSION MODELS; MULTIFACTORIAL RISK INDEX; MAJOR NONCARDIAC SURGERY; NONTHORACIC SURGERY; RESPIRATORY-FAILURE; PROGNOSTIC MODEL; POPULATION; IMPACT; INTUBATIONCohort study
researchProduct

Multidimensional Prognostic Index and Mortality in Intermediate Care Facilities: A Retrospective Study.

2021

Multidimensional prognostic index (MPI) is a frailty assessment tool used for stratifying prognosis in older hospitalized people, but data regarding older people admitted to intermediate care facilities (ICFs) are missing. The aim of this study is to evaluate whether MPI can predict mortality in older patients admitted to the ICFs. MPI was calculated using different domains explored by a standard comprehensive geriatric assessment and categorized into tertiles (MPI-1 ≤ 0.20, MPI-2 0.20–0.34, MPI-3 &gt

medicine.medical_specialtyIndex (economics)Intermediate Care FacilityArticle03 medical and health sciences0302 clinical medicineInternal medicineRisk of mortalityMedicine030212 general & internal medicinebusiness.industryHazard ratioRArea under the curveRegression analysisRetrospective cohort studyGeneral MedicinemortalityConfidence intervalmultidimensional prognostic indexintermediate careprognosis.Medicineprognosisbusiness030217 neurology & neurosurgeryJournal of clinical medicine
researchProduct

Clinicogenetic Risk Models in Patients Randomized to Receive Consolidative Autologous Stem-Cell Transplantation after Frontline R-CHOP for Advanced F…

2018

Abstract Introduction: Advanced follicular lymphoma (FL) is a clinically and molecularly heterogeneous disease. About 20% of patients have early progression of disease (POD) and short overall survival (OS). We have previously shown that integration of lymphoma-specific gene mutations and clinical factors improves pretreatment risk stratification (Pastore, 2015) and prediction of early POD (i.e., within 24 months, POD24; Jurinovic, 2016). Recently, we have shown that high-dose therapy (HDT) followed by autologous stem-cell transplantation (ASCT) is an effective treatment option for eligible patients with high-risk disease as defined by POD24 (Jurinovic, 2018). Here, we aimed to explore wheth…

medicine.medical_specialtyIntention-to-treat analysisbusiness.industryImmunologyFollicular lymphomaCell BiologyHematologyGene mutationmedicine.diseaseBiochemistryTransplantationAutologous stem-cell transplantationInternational Prognostic IndexInternal medicineCohortmedicineIn patientbusinessBlood
researchProduct

Evaluating the effectiveness and risks of oral anticoagulant treatments in multimorbid frail older subjects with atrial fibrillation using the multid…

2018

Background: Previous studies suggested that a different risk of mortality may influence the oral anticoagulant prescription in older patients with atrial fibrillation (AF). Recently, the Multidimensional Prognostic Index (MPI) demonstrated a high grade of accuracy, calibration and feasibility to predict mortality in hospitalized and community-dwelling older people. Prognostic information, as calculated by the MPI, however, is not included in the decision algorithm of treatments in older patients with AF Purpose: The aim of this international multicenter prospective observational study was to evaluate whether a different prognostic profile, as determined by the MPI, is associated with differ…

medicine.medical_specialtyMuldimensional Prognostic IndexPopulationlaw.invention03 medical and health sciencesElderly0302 clinical medicineRandomized controlled triallawInternal medicineAtrial FibrillationmedicineRisk of mortality030212 general & internal medicineMedical prescriptioneducationAnticoagulants; Atrial Fibrillation; Elderly; Frailty; Muldimensional Prognostic Indexeducation.field_of_studyFrailtybusiness.industryAnticoagulantWarfarinAnticoagulantsAtrial fibrillationmedicine.diseaseRelative riskObservational studyGeriatrics and GerontologybusinessGerontology030217 neurology & neurosurgerymedicine.drugEuropean Geriatric Medicine
researchProduct

Heat Shock Protein 70 Serum Levels Differ Significantly in Patients with Chronic Hepatitis, Liver Cirrhosis, and Hepatocellular Carcinoma

2014

Members of the heat shock protein 70 (HSP70) family play an important role in assisting protein folding, preventing protein aggregation and transport of proteins across membranes under physiological conditions. Following environmental (i.e., irradiation, chemotherapy), physiological (i.e., cell growth, differentiation), and pathophysiological (i.e., inflammation, tumorigenesis) stress, the synthesis of heat shock proteins (HSPs) is highly up-regulated, whereas protein synthesis in general is reduced. In contrast to normal cells, many tumor entities including hepatocellular carcinoma (HCC) overexpress HSP70, the major-stress-inducible member of the HSP70 family, present it on their cell surf…

medicine.medical_specialtyPathologyCirrhosismedicine.medical_treatmentliver cirrhosisImmunologyInflammationmedicine.disease_causeGastroenterology03 medical and health sciencesLiver disease0302 clinical medicineInternal medicinemedicineImmunology and AllergyHCCprognostic biomarker030304 developmental biologyOriginal Research0303 health sciencesChemotherapyserum HSP70business.industryHcc ; Chronic Hepatitis ; Inflammation ; Liver Cirrhosis ; Prognostic Biomarker ; Serum Hsp70medicine.diseasePathophysiology3. Good healthHsp70HCC serum HSP70 prognostic biomarker chronic hepatitis inflammation liver cirrhosisinflammation030220 oncology & carcinogenesisHepatocellular carcinomachronic hepatitismedicine.symptomCarcinogenesisbusinessFrontiers in Immunology
researchProduct

Gene Rearrangements and Other Molecular Features in Aggressive B-Cell Lymphomas of Patients with and without HIV-Infection

2015

Abstract Aggressive B-cell Lymphomas are the second most frequent AIDS-defining cancers. Few studies have compared the molecular characteristics of aggressive B-cell lymphomas in patients with and without HIV-infection; and to our knowledge, there are no reports comparing the incidence of gene rearrangements between the two groups and their impact on outcome in series treated with RCHOP. We retrospectively studied two series of patients with (N=32) and without HIV-infection (N=43) with diffuse large B-cell lymphomas (DLBCL) NOS (75% and 70%, respectively), T-rich DLCBL (13% and 5%), transformed DLBCL (3% and 14%) and double-hit (DH) DLCBL (9% and 11%) [defined by translocations affecting MY…

medicine.medical_specialtyPathologybusiness.industryIncidence (epidemiology)ImmunologyFollicular lymphomaCell BiologyHematologyCHOPmedicine.diseaseBiochemistryGastroenterologyLymphomaExact testInternational Prognostic IndexInternal medicinemedicineProgression-free survivalbusinessDiffuse large B-cell lymphomaBlood
researchProduct

Effect of Prognostic Risk Classification on Temsirolimus Efficacy and Safety Outcomes in Patients with Relapsed/Refractory Mantle Cell Lymphoma

2011

Abstract Abstract 2708 Background: The simplified Mantle Cell Lymphoma International Prognostic Index (MIPI) has been shown to be a good predictor of patient survival (Blood 2008;111:558–65; Blood 2010;115:1530–1533). This post hoc study analyzed data from a randomized, phase III clinical trial investigating temsirolimus (TEM) in relapsed/refractory mantle cell lymphoma (MCL) in which TEM 175/75 (175 mg for first 3 weeks then 75 mg weekly) demonstrated significantly longer progression-free survival (PFS) vs investigator's choice of therapy (INV; 4.8 vs 1.9 months, respectively; hazard ratio [HR]=0.44; P=.0009; J Clin Oncol 2009;27:3822–9). Patients receiving TEM 175/25 (175 mg for first 3 w…

medicine.medical_specialtyPerformance statusAnemiabusiness.industryIncidence (epidemiology)ImmunologyHazard ratioCell BiologyHematologymedicine.diseaseBiochemistryGastroenterologyTemsirolimusInternational Prognostic IndexRenal cell carcinomaInternal medicinemedicineMantle cell lymphomabusinessmedicine.drugBlood
researchProduct

Results of a Phase II Study of Pixantrone in Combination with Cyclophosphamide, Vincristine, and Prednisone in Patients with Relapsed Aggressive Non-…

2006

Abstract Background: Pixantrone is a novel aza-anthracenedione with less cardiotoxicity and superior activity compared to doxorubicin and mitoxantrone in murine leukemia and lymphoma tumor models. Pixantrone as single agent therapy led to major responses in patients (pts) with multiply relapsed aggressive non-Hodgkin’s lymphoma (NHL), including diffuse large B-cell lymphoma (DLCL). In a phase I dose-ranging study of pixantrone (80 to 180 mg/m2) replacing doxorubicin (CPOP) in a CHOP-like regimen, the optimal dose (RD) from that study was found to be 150 mg/m2. Methods: In this international, multi-center, phase II study the primary objective was to assess the efficacy and safety of the CPOP…

medicine.medical_specialtyPixantroneAnthracyclinebusiness.industryImmunologyFollicular lymphomaCell BiologyHematologymedicine.diseaseBiochemistryGastroenterologyNon-Hodgkin's lymphomaSurgerychemistry.chemical_compoundInternational Prognostic Indexchemistryhemic and lymphatic diseasesInternal medicineMedicineMantle cell lymphomabusinessDiffuse large B-cell lymphomaFebrile neutropeniaBlood
researchProduct

Efficacy, Safety, and Confirmation of the Recommended Phase 2 Dose of Ruxolitinib Plus Panobinostat in Patients with Intermediate or High-Risk Myelof…

2014

Abstract Background: Myelofibrosis (MF) is a clonal neoplastic disease resulting in bone marrow fibrosis, splenomegaly, and debilitating constitutional symptoms. The Janus kinase (JAK) pathway is often dysregulated in MF, and agents targeting this pathway have demonstrated efficacy in this disease. Ruxolitinib (RUX), a potent JAK1/JAK2 inhibitor, demonstrated superiority in spleen volume reduction, symptom improvement, and survival compared with the control arm in the phase III COMFORT-I and COMFORT-II studies. Panobinostat (PAN), a potent pan-deacetylase inhibitor (pan-DACi), inhibits JAK signaling through disruption of the interaction of JAK2 with the protein chaperone heat shock protein …

medicine.medical_specialtyRuxolitinibThrombocytosisCombination therapybusiness.industryAnemiaImmunologyCell BiologyHematologymedicine.diseaseBiochemistryDiscontinuationchemistry.chemical_compoundchemistryInternational Prognostic Scoring SystemInternal medicinePanobinostatImmunologymedicinebusinessMyelofibrosismedicine.drugBlood
researchProduct